pd 153035 and topotecan

pd 153035 has been researched along with topotecan in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alqahtani, S; Ashby, CR; Bates, SE; Chen, ZS; Deng, T; Gupta, P; Kaddoumi, A; Lei, YX; Wang, YJ; Wurpel, JND; Zhang, GN; Zhang, YK	1

Other Studies

1 other study(ies) available for pd 153035 and topotecan

Article	Year
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. Cancer letters, 2018, 06-28, Volume: 424 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Proteins; Quinazolines; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays	2018

Article

Year

Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.

Cancer letters, 2018, 06-28, Volume: 424

Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Proteins; Quinazolines; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays

2018